HeartRhythm

MARCH 31, 2025

Studies have shown detrimental effects of atrial fibrillation (AF) occurrence among patients with heart failure (HF) with a preserved ejection fraction (HFpEF). Ablative therapy may counter this risk, but the impact of timing of ablation in paroxysmal vs. persistent AF is unclear.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

DAIC

JUNE 4, 2024

American College of Cardiology (ACC) and American Heart Association (AHA) Issue New Hypertrophic Cardiomyopathy (HCM) Management Guidelines 2. New Study Published in JACC: Heart Failure Reveals that Despite Significant Efforts to Improve Acute Heart Failure Treatment Over the Past 20 Years, Management Remains Unchanged 3.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Peripheral Arterial Disease Heart Failure Cardiomyopathy 105

European Journal of Heart Failure

NOVEMBER 29, 2023

ABSTRACT Aims Heart failure outcomes remain poor despite advances in therapy. The European Society of Cardiology Heart Failure III Registry (ESC HF III Registry) aims to characterize HF clinical features and outcomes and to assess implementation of guideline-recommended therapy in Europe and other ESC affiliated countries.

Heart Failure 75

Heart Failure Preserved Ejection Fraction Quality of Life Biomarkers 75

Circulation

JANUARY 22, 2025

Circulation, Ahead of Print. Optimal NT-proBNP cut points for HFpEF rule out (optimizing sensitivity) and rule in (optimizing specificity) were derived and tested, stratified by obesity and atrial fibrillation.

Preserved Ejection Fraction 55

Preserved Ejection Fraction Outpatient Heart Failure BMI 55

European Journal of Heart Failure

OCTOBER 30, 2023

In patients with heart failure with preserved ejection fraction (HFpEF), abnormal global longitudinal strain (GLS) is a strong predictor for clinical events and can help identity patients who are at risk for future decline in left ventricular ejection fraction (LVEF). After a median follow-up of 4.6 years,

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Hospital 40

Circulation

NOVEMBER 11, 2024

As heart failure with preserved ejection fraction (HFpEF) comprises half of all heart failure cases, understanding its management and effect on outcomes is crucial. Multivariate logistic and linear regression analyses were performed, adjusting for multiple patient and hospital confounders.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Inpatient Heart Failure Cardiogenic Shock 40

Journal of Cardiovascular Electrophysiology

DECEMBER 17, 2024

Abstract Background Heart failure (HF) with preserved ejection fraction (HFpEF) and atrial fibrillation (AF) are associated with high morbidity and mortality. HFpEF were defined as HFA-PEFF score of 5 or 6 and left ventricular ejection fraction 50% before the initial CA. 423 by a log-rank test).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

Journal of Cardiovascular Electrophysiology

FEBRUARY 13, 2024

Abstract Introduction Heart failure (HF) and atrial fibrillation (AF) frequently co-exist. Contemporary classification of HF categorizes it into HF with reduced ejection fraction (HFrEF), HF with mildly reduced ejection fraction (HFmrEF), and HF with preserved ejection fraction (HFpEF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Hospital 40

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Empagliflozin reduced the risk of lower respiratory tract infections. CI, confidence interval; HR, hazard ratio. Aims Lower respiratory tract infections (LRTI) are common worldwide.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

JAMA Cardiology

SEPTEMBER 30, 2021

This cohort study examines the prevalence of epicardial coronary artery disease and coronary microvascular dysfunction in hospitalized patients with heart failure with preserved ejection fraction.

Coronary Artery Disease 40

Coronary Artery Disease Preserved Ejection Fraction Heart Failure Hospital 40

Frontiers in Cardiovascular Medicine

OCTOBER 10, 2024

ObjectiveTo investigate the therapeutic effect of Vericiguat combined with “new quadruple” drugs on patients with heart failure (HF).MethodsFrom Patients diagnosed with preserved ejection fraction (HFpEF) were treated with Vericiguat combined with “ARNI, BB, SGLT2i” therapy.

Heart Failure 52

Heart Failure Preserved Ejection Fraction Cardiac Function Quality of Life 52

HeartRhythm

APRIL 30, 2024

Previous studies have demonstrated significant morbidity and mortality in patients with heart failure (HF) with reduced ejection fraction (HFrEF), particularly with accompanying atrial fibrillation (AF).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

MARCH 30, 2025

Metabolic dysfunction and incident heart failure. Aims The extent to which metabolic syndrome (MetS) severity influences subclinical myocardial remodelling, heart failure (HF) incidence and subtypes, remains unclear. CI, confidence interval; MetS, metabolic syndrome.

Heart Failure 40

Heart Failure Preserved Ejection Fraction Biomarkers BMI 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Meta-analysis on the main outcomes of angiotensin receptorneprilysin inhibitor (ARNI) in heart failure (HF) patients with end-stage kidney disease (ESKD) on dialysis. Abstract Aims Angiotensin receptorneprilysin inhibitor (ARNI) has played an increasingly important role in the management of heart failure (HF).

Kidney Disease 49

Kidney Disease Heart Failure Preserved Ejection Fraction Blood Pressure 49

HeartRhythm

APRIL 30, 2024

Atrial fibrillation (AF) with comorbid heart failure with preserved ejection fraction (HFpEF) presents a significant management challenge. While the association between AF and heart failure with reduced ejection fraction is extensively studied, the correlation between AF and HFpEF remains less explored.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Hospital 40

Journal of the American Heart Association

JANUARY 19, 2024

BackgroundSystemic chronic inflammation plays a role in the pathophysiology of both heart failure with preserved ejection fraction (HFpEF) and metabolic dysfunction‐associated fatty liver disease. The study outcome was time to the first hospitalization for HF. In 10 019 middle‐aged individuals (mean age, 63.3±10.6

Heart Failure 45

Heart Failure Preserved Ejection Fraction Hospital Heart Disease 45

Circulation

NOVEMBER 11, 2024

Left ventricular ejection fractions were similar in both MAC (58.3 + 11.9) Conclusion:Among patients hospitalized with ‘diastolic heart failure’ MAC is associated with worse cardiovascular outcomes. vs non-MAC (58.2 + 12.6). Median follow-up was 423 days (MAC group) and 575 days (non-MAC group).

Heart Failure 40

Heart Failure Preserved Ejection Fraction Bicuspid/Mitral Outcomes 40

DAIC

JANUARY 23, 2024

Getty Images milla1cf Tue, 01/23/2024 - 13:38 January 23, 2024 — Sequana Medical NV , a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, announced that an independent Data and Safety Monitoring Board (DSMB) approved the start of the randomized cohort in MOJAVE , the US Phase 1/2a study of DSR 2.0

Heart Failure 104

Heart Failure Preserved Ejection Fraction Hypertension Cancer 104

HeartRhythm

JUNE 23, 2024

Furthermore, among patients with heart failure, both reduced and preserved ejection fraction, catheter ablation reduces heart failure hospitalizations and mortality.1-10

Preserved Ejection Fraction 40

Preserved Ejection Fraction Ablation Heart Failure Atrial Fibrillation 40

HeartRhythm

MARCH 31, 2025

A 76-year-old male with heart failure and preserved ejection fraction presented with recurrent falls. He underwent dual-chamber pacemaker placement at an outside hospital. An implantable loop recorder revealed profound sinus bradycardia, AF and offset sinus pauses.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Pacemaker Bradycardia Heart Failure 40

Circulation: Cardiovascular Quality & Outcomes

APRIL 21, 2025

We then assessed the real-world generalizability of TOPCAT by developing a novel statistic, the phenotypic distance metric, to quantify the representation of TOPCAT participants within EHR patients.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Cardiac Function Hospital 40

JAMA Cardiology

JULY 23, 2024

Among patients with heart failure with preserved ejection fraction (HFpEF), right ventricular (RV) dysfunction is strongly associated with an increased risk of morbidity and mortality.

Preserved Ejection Fraction 42

Preserved Ejection Fraction Heart Failure Pulmonary Exercise 42

European Journal of Heart Failure

APRIL 13, 2025

The beneficial effects of finerenone in patients with heart failure (HF) and mildly reduced or preserved ejection fraction were consistent, regardless of a history of chronic obstructive pulmonary disease (COPD) status.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Pulmonary Peripheral Arterial Disease 40

DAIC

MARCH 26, 2025

Food and Drug Administration (FDA) accepted its supplemental new drug application (sNDA) and granted Priority Review designation for KERENDIA(finerenone) for the treatment of adult patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of 40%, i.e., mildly reduced LVEF (HFmrEF) or preserved LVEF (HFpEF).

Heart Failure 52

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor 52

Science Daily - Heart Disease

SEPTEMBER 2, 2024

Finerenone reduced the composite of total first and recurrent heart failure (HF) events (hospitalizations for HF or urgent HF visits) and cardiovascular death in patients with HF and mildly reduced or preserved ejection fraction, according to an international clinical trial.

Preserved Ejection Fraction 129

Preserved Ejection Fraction Heart Failure Hospital 129

Frontiers in Cardiovascular Medicine

FEBRUARY 6, 2025

However, the relationship between PWR and adverse outcomes in patients with acute decompensated heart failure (ADHF) remains unclear. The primary outcome measure was all-cause mortality within 30 days of hospitalization. vs. 0.87, P for interaction=0.0067).ConclusionThis vs. 0.87, P for interaction=0.0067).ConclusionThis

Heart Failure 40

Heart Failure Hospital Preserved Ejection Fraction Outcomes 40

DAIC

APRIL 2, 2024

Yakubu Bene-Alhasan, MD milla1cf Tue, 04/02/2024 - 12:14 April 2, 2024 — People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure.

Heart Failure 105

Heart Failure Preserved Ejection Fraction Research Risk Factors 105

European Journal of Heart Failure

DECEMBER 13, 2023

BMI, body mass index; CI, confidence interval; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide. ABSTRACT Aim Chronic obstructive pulmonary disease (COPD) is common in heart failure with a mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) and is associated with worse outcomes.

Preserved Ejection Fraction 75

Preserved Ejection Fraction Heart Failure Pulmonary Quality of Life 75

Journal of the American Heart Association

DECEMBER 14, 2024

The main outcome was the composite of allcause mortality and first HF hospitalization. The mean age, body mass index, left ventricular ejection fraction, and EAT volume were 57.0 During a median followup of 34 months, 169 patients (24.4%) died or were hospitalized for HF. Of 692 participants, 41.3% were women.

Preserved Ejection Fraction 58

Preserved Ejection Fraction Heart Failure Hospital Outcomes 58

DAIC

FEBRUARY 22, 2024

The study, which is testing a novel rehabilitation program designed for older patients hospitalized with acute heart failure, is funded by a five-year, $30 million grant , awarded to Wake Forest University School of Medicine in 2022 by the National Institute of Aging, part of the National Institutes of Health.

Heart Failure 105

Heart Failure Research Preserved Ejection Fraction Hospital 105

European Journal of Heart Failure

DECEMBER 19, 2024

BNP, B-type natriuretic peptide; CV, cardiovascular; EF, ejection fraction; eGFR, estimated glomerular filtration rate; EP, endpoint; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SwedeHF, Swedish Heart Failure Registry; US, United States.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outpatient Atrial Fibrillation 40

European Journal of Heart Failure

DECEMBER 7, 2023

ABSTRACT Background Left atrial (LA) myopathy is increasingly recognized as an important phenotypic trait in heart failure (HF) with preserved ejection fraction (HFpEF). 2.92, p = 0.01).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Exercise Tricuspid 40

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 75

Heart Failure Quality of Life Preserved Ejection Fraction Hospital 75

European Journal of Heart Failure

DECEMBER 15, 2024

A summary of effect of sacubitril/valsartan in heart failure with preserved ejection fraction across the age spectrum. The primary composite outcome was total HF hospitalizations and cardiovascular (CV) death.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Laboratory Echocardiogram 40

Journal of Cardiovascular Electrophysiology

OCTOBER 21, 2024

Abstract Introduction Catheter ablation for atrial fibrillation (AF) reduces heart failure (HF) hospitalization in patients with HF with preserved ejection fraction (HFpEF). The primary endpoint was a composite of death from any cause or hospitalization for worsening HF.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Atrial Fibrillation Heart Failure Ablation 40

European Journal of Heart Failure

FEBRUARY 5, 2025

Beta-blockers are commonly used in patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF). Methods and results We pooled individual patient data from four large HFmrEF/HFpEF trials (I-Preserve, TOPCAT, PARAGON-HF, and DELIVER).

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Outcomes Atrial Fibrillation 40

DAIC

APRIL 6, 2024

The trial, called RELIEVE-HF , is the first randomized placebo-procedure controlled trial of interatrial shunting that included patients with both major types of heart failure : heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF).

Heart Failure 81

Heart Failure Quality of Life Outcomes Preserved Ejection Fraction 81